Bioneercorporation: Revenue Growth Continues While Profits Stay Thin and the Share Price Swings

Thesis

The data supports a picture of a growing top line with weak and uneven profitability. Revenue has risen each year since 2022, from ₩218.4B to ₩330.1B in 2025, and operating income turned positive in 2025 at ₩15.2B after a loss in 2024. Trailing operating income of ₩6.2B is lower than the 2025 figure, and net income is still negative, so the recovery is not yet confirmed.

The shares trade at 1.0x book value and 0.6x sales, well below the 1.6x to 6.2x year-end P/B range of recent years. That reflects lower returns, not necessarily a mispricing. Foreign ownership fell from 7.4% to 3.6% in 60 days, and the 20-day foreign flow was slightly negative, while retail was net positive. No recent news headlines are available in the data, so the reasons for the price moves cannot be assessed.

Business overview

Bioneercorporation is a KOSDAQ-listed company in the biotech and pharma sector, founded in 1992 and listed in December 2005. It has 25,810,291 listed shares and a market capitalization of about ₩205.2B. Enterprise value is about ₩164.0B. Annual revenue grew from ₩223.7B in 2021 to ₩330.1B in 2025, though the operating margin fell from 21.0% in 2021 to 4.6% in 2025. The data does not break down the revenue by product or segment.

Model estimate of fair value

Bear

₩10,558

+49%

Base

₩18,543

+162%

Bull

₩32,015

+353%

Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal.

Base case of the 5-year discounted cash flow model on the stock's Valuation tab (statements TTM to H1 2026; discount rate 7.5%). Bear and Bull move the main assumptions by fixed steps. See and change the assumptions

Filings and data used

• Insider shareholding reportOct 12, 2026
• Insider shareholding reportOct 12, 2026
• Half-year report (Jun 2026)Aug 14, 2026
• Quarterly report (Mar 2026)May 15, 2026
• Change of Department AffiliationApr 30, 2026
• Preliminary earnings (consolidated)Apr 30, 2026
• Amended: Annual general meeting resultsApr 7, 2026
• Amended: Annual general meeting resultsApr 2, 2026
• Amended: Annual general meeting resultsApr 2, 2026
• Annual general meeting resultsMar 31, 2026
• Report on Appointment, Dismissal, or Mid-Term Resignation of Independent DirectorsMar 31, 2026
• Amended: Annual report (Dec 2025)Mar 24, 2026
• Daily prices up to 2026-10-16
• Financial statements, trailing 12 months as of H1 2026
• Our fair value model, statements as of TTM to H1 2026

Report history

1. Oct 21, 2026Update noteModel fair value changeBioneercorporation: Model Fair Value Estimate Cut by 67% to ₩6,119 per Share
2. Oct 18, 2026InitiationStart of coverage (reader request)Bioneercorporation: Revenue Growth Continues While Profits Stay Thin and the Share Price Swings